Psylo & CSIRO: A partnership to study neuroplasticity of new psychedelic compounds

July 11th, 2022

Benzinga, Other, 09/07/2022, Lara Goldstein
Pre-clinical biotech psychedelics company Psylo has signed an agreement with Australia’s national science agency CSIRO to collaboratively investigate the therapeutic potential of the company’s lead drug candidates. Based at the University of New South Wales in Sydney, the company’s goal is to produce highly optimized and proprietary psychedelic therapeutics for current and emerging clinical needs.

Read more: